Last reviewed · How we verify
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure; the combination with hydrochlorothiazide adds a diuretic to enhance sodium and water excretion.
Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure; the combination with hydrochlorothiazide adds a diuretic to enhance sodium and water excretion. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.
At a glance
| Generic name | VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker (ARB) + thiazide diuretic |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone release, thereby reducing blood pressure and cardiac workload. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water loss to further lower blood pressure. The combination provides complementary antihypertensive effects.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction with left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Hypokalemia (with HCTZ component)
- Cough
- Headache
- Hypotension
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH (PHASE2)
- BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (PHASE3)
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension (PHASE3)
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil (PHASE3)
- Hypertension and Cardiovascular Risk Factors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE CI brief — competitive landscape report
- VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE updates RSS · CI watch RSS
- Novartis portfolio CI